Cardiovascular Devices: Elixir Medical Corporation

• Publication date: October 2011

This report is a source for data, analysis and actionable intelligence on the Elixir Medical Corporation portfolio of new product development . The report provides detailed analysis on each pipeline product with data on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date. Each pipeline product is profiled to cover data on product description...

This report is a source for data, analysis and actionable intelligence on the Elixir Medical Corporation portfolio of new product development . The report provides detailed analysis on each pipeline product with data on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover data on product description, function, technology, indication, and application. The report is also supplemented with a detailed industry player profile and data on clinical trials, wherever applicable.

Scope of the Research

- Detailed industry player profile with data on business description, key industry player facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the new product development, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional data on product description, function, technology, indication(s), and application.
- Data on relevant clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with data on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, industry ing and sales strategies.
- Exploit Merger and Acquisition opportunities by identifying industry players with the most innovative pipeline.
- Develop successful market-entry strategies .
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ new product development through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

Cardiovascular Devices Industry

Data table of Contents
Data table of Contents 2
List of Tables 3
List of Figures 4
Key Facts 5
Elixir Medical Corporation - Major Products and Services 6
Elixir Medical Corporation Pipeline Products by Equipment Type 7
Elixir Medical Corporation Pipeline Products by Development Stage 9
Elixir Medical Corporation Pipeline Products by Therapy Area 11
Elixir Medical Corporation Pipeline Products by Trial Phase 13
Elixir Medical Corporation Pipeline Products by Milestone Summary 15
Bioabsorbable Stent System 17
Product Status 17
Product Description 17
DESyne BD November olimus Eluting Coronary Stent System 17
Product Status 17
Product Description 17
Product Milestone 18
DESyne BD November olimus Eluting Coronary Stent System Clinical Trial 18
DESyne November olimus Eluting Coronary Stent System 19
Product Status 19
Product Description 19
Myolimus Eluting Coronary Stent-Bioabsorbable Polymer 19
Product Status 19
Product Description 19
Product Milestone 20
Myolimus Eluting Coronary Stent-Bioabsorbable Polymer Clinical Trial 20
Myolimus Eluting Coronary Stent-Durable Polymer 21
Product Status 21
Product Description 21
Product Milestone 21
Myolimus Eluting Coronary Stent-Durable Polymer Clinical Trial 21
November olimus Eluting Coronary Stent System-Durable Polymer 22
Product Status 22
Product Description 22
Product Milestone 22
November olimus Eluting Coronary Stent System-Durable Polymer Clinical Trial 23
Elixir Medical Corporation - Top Competitors 26
Elixir Medical Corporation - Key Executives 27
Elixir Medical Corporation - Operations and Subsidiaries 28
Head Office 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29


List of Tables

Elixir Medical Corporation, Major development 1
Elixir Medical Corporation Key Pipeline Products by Equipment Type 1
Elixir Medical Corporation Key Pipeline Products by Therapy Area 1
Elixir Medical Corporation Key Pipeline Products by Development Stage 1
Elixir Medical Corporation Key Pipeline Products by Trial Phase 1
Elixir Medical Corporation, Major development 5
Elixir Medical Corporation, Major Products and Services 6
Elixir Medical Corporation Number of Pipeline Products by Equipment Type 7
Elixir Medical Corporation Pipeline Products by Equipment Type 8
Elixir Medical Corporation Number of Pipeline Products by Development Stage 9
Elixir Medical Corporation Pipeline Products by Development Stage 10
Elixir Medical Corporation Number of Pipeline Products by Therapy Area 11
Elixir Medical Corporation Pipeline Products by Therapy Area 12
Elixir Medical Corporation Number of Pipeline Products by Trial Phase 13
Elixir Medical Corporation Pipeline Products by Trial Phase 14
Elixir Medical Corporation Number of Pipeline Products By Milestone Summary 15
Elixir Medical Corporation Pipeline Products by Milestone Summary 16
Bioabsorbable Stent System - Product Status 17
Bioabsorbable Stent System - Product Description 17
DESyne BD November olimus Eluting Coronary Stent System - Product Status 17
DESyne BD November olimus Eluting Coronary Stent System - Product Description 17
DESyne BD November olimus Eluting Coronary Stent System - Product Milestone 18
DESyne BD November olimus Eluting Coronary Stent System - November olimus Eluting Coronary Stent System with Bioabsorbable Polymer: Nine-Month Clinical and Six-Month Angiographic Results 18
DESyne November olimus Eluting Coronary Stent System - Product Status 19
DESyne November olimus Eluting Coronary Stent System - Product Description 19
Myolimus Eluting Coronary Stent-Bioabsorbable Polymer - Product Status 19
Myolimus Eluting Coronary Stent-Bioabsorbable Polymer - Product Description 19
Myolimus Eluting Coronary Stent-Bioabsorbable Polymer - Product Milestone 20
Myolimus Eluting Coronary Stent-Bioabsorbable Polymer - First-In-Man Study Of The Myolimus Eluting Coronary Stent System 20
Myolimus Eluting Coronary Stent-Durable Polymer - Product Status 21
Myolimus Eluting Coronary Stent-Durable Polymer - Product Description 21
Myolimus Eluting Coronary Stent-Durable Polymer - Product Milestone 21
Myolimus Eluting Coronary Stent-Durable Polymer - Elixir Medical Corporation Announced Positive First-In-Man Results From 21
Three Drug Eluting Coronary Stent Systems 21
November olimus Eluting Coronary Stent System-Durable Polymer - Product Status 22
November olimus Eluting Coronary Stent System-Durable Polymer - Product Description 22
November olimus Eluting Coronary Stent System-Durable Polymer - Product Milestone 22
November olimus Eluting Coronary Stent System-Durable Polymer - A Randomized, Single Blind, Consecutive Enrollment Evaluation Of The Elixir November olimus-Eluting Coronary Stent System With Durable Polymer Compared To The Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System In The Treatment Of Patients With De November o Native Coronary Artery Lesions And A Non-Randomized, Consecutive Enrollment Evaluation Of The Elixir November olimus-Eluting Coronary Stent System With Bioabsorbable Polymer Compared To Contemporary Controls In The Treatment Of Patients With De November o Native Coronary Artery Lesions 23
November olimus Eluting Coronary Stent System-Durable Polymer - Elixir First-In-Man Trial To Study The Feasibility And Safety Study Of November olimus Drug Eluting Coronary Stent System With Durable Polymer-Twenty-Four-Month Clinical Trial 24
November olimus Eluting Coronary Stent System-Durable Polymer - First-In Man Trial To Test The Feasiblity And Clinical Safety Of November olimus Drug Eluting Coronary Stent System With Durable Polymer - 9 Months 25
Elixir Medical Corporation, Key Executives 27


List of Figures

Elixir Medical Corporation Pipeline Products by Equipment Type 7
Elixir Medical Corporation Pipeline Products by Development Stage 9
Elixir Medical Corporation Pipeline Products by Therapy Area 11
Elixir Medical Corporation Pipeline Products by Trial Phase 13
Elixir Medical Corporation Pipeline Products by Milestone Summary 15

Companies mentioned Clinical Instrument International, Inc.
Icon Interventional Systems, Inc.
Cook Incorporated
CardioMind, Inc.